# A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

> **NCT05694767** · PHASE2 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 22 (actual)

## Conditions studied

- Immune Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** CM313 Injection

## Key facts

- **NCT ID:** NCT05694767
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-22
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05694767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05694767, "A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05694767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*